Metabolic health is not a number.
It is a continuous story told in signals physicians rarely see.

MetAi is grounded in peer-reviewed literature across metabolic health, longevity medicine, body composition science, biometric monitoring, and behaviour change. Every signal we track, every alert threshold, and every clinical protocol traces back to a specific published finding.

Lancet Diabetes & Endocrinology · 2024
74.7%
of weight regain occurs within 12 months of stopping GLP-1 therapy — alongside full reversal of cardiometabolic improvements.
STEP 1 Trial Extension · Wilding et al.
Lancet · Muscle Matters · 2024
25–39%
of GLP-1 trial weight loss is lean tissue, not fat. Without body composition monitoring, this is entirely invisible.
Prado, Phillips, Gonzalez, Heymsfield
JAMA · SURMOUNT-4 · 2024
89.5%
of weight loss maintained with continued tirzepatide vs near-complete reversal on placebo — outcomes are a function of continuity.
Aronne, Sattar, Horn, Bays et al.

Metabolic health is the upstream variable. Everything else follows.

Episodic care cannot produce durable metabolic outcomes. The published evidence is clear — every cardiometabolic improvement reverses when continuity is withdrawn, every protocol depends on what happens during the 364 days between appointments.

Conventional care produces six clinical snapshots a year. MetAi produces three hundred and sixty-five — that's how often biology actually moves. Body composition, biometrics, and bloodwork are the three signal domains where the metabolic story actually unfolds. Together they define whether a patient's trajectory is heading toward longevity or away from it.

This page documents the published research that shaped how we designed MetAi. None of it is marketing. Every claim cites a peer-reviewed source.

What the metabolic health story is actually made of

Weight is a proxy for three underlying clinical realities that physicians need to see directly — and that change continuously between every appointment. Each domain tells a different chapter of the metabolic health story.

Domain 01

Body composition — lean mass, visceral fat, and the metabolic signals weight conceals

Weight tells you how much. Body composition tells you of what. Lean tissue mass drives metabolic rate, glucose disposal, and functional independence with age. Visceral fat is the adipose compartment causally linked to insulin resistance, cardiovascular disease, type 2 diabetes, and all-cause mortality. A scale measures neither.

Published finding · Visceral fat & mortality
Causal
The relationship between visceral fat and longevity is causal — not correlational. Epidemiological evidence links cumulative visceral fat exposure to CVD, T2D, stroke, and all-cause mortality.
Liu Q et al. · Journal of Cachexia, Sarcopenia & Muscle · 2025
MetAi response: Daily bioelectrical impedance analysis at home, 25+ metrics streaming to the physician dashboard — lean mass, visceral fat index, skeletal muscle mass, metabolic rate.
Domain 02

Biometrics — cardiovascular & sleep signals that precede clinical events

HRV reflects autonomic function and physiological resilience — declining with metabolic stress, sleep disruption, and cardiovascular risk long before symptoms. Resting heart rate, SpO₂, and sleep architecture are equally sensitive early indicators that respond to dietary changes and medication effects in ways that 4–6 week appointment cycles structurally cannot capture.

Published finding · Sleep & sarcopenia
2.42×
Increased risk of sarcopenia in individuals with long sleep disorders, per Cox regression over 8+ years of follow-up. Sleep architecture is a clinical indicator of metabolic and musculoskeletal trajectory — not wellness.
ALEXANDROS Longitudinal Study · BMC · 2024 (HR=2.42, 95% CI 1.20–4.91)
MetAi response: Continuous HR, HRV, SpO₂, skin temperature, and sleep staging via medical-grade wearables — analysed by MetAi and surfaced to your care team before symptoms emerge.
Domain 03

Bloodwork trends — the metabolic trajectory visible in labs before symptoms declare

Fasting glucose, HbA1c, lipid fractions, inflammatory markers, liver enzymes, and hormone panels trend before disease is declared. They respond to treatment weeks before weight changes — and reverse alongside clinical improvements when continuity is withdrawn. Interpreting these as isolated points at each visit misses the directional story that matters for longevity.

Published finding · Bloodwork & longevity
Predictive
Blood biomarkers of atherosclerosis, metabolism, inflammation, and insulin resistance are independently associated with longevity — and their trends track closely with dietary intervention and metabolic treatment response.
JAMA 2024 · Mediterranean diet biomarker study · Life Extension Review · 2025
MetAi response: AI-interpreted lab results with automatically calculated clinical indices — ASCVD risk, CKD-EPI, AHI, MELD-Na — integrated alongside body composition and biometric data.

The evidence base MetAi is built on

Nine peer-reviewed papers shape every protocol, every alert threshold, every measurement frequency in the platform. Authorship, journal, and year are listed in full — request access to any full paper via science@metai.health.

Lancet D&E
Lancet Diabetes & Endocrinology · 2024
Muscle matters: the effects of medically induced weight loss on skeletal muscle
Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB
25–39% of GLP-1 trial weight loss is lean tissue, not fat. Without body composition monitoring, this is entirely invisible. Establishes daily BIA as a clinical necessity — not optional — in physician-supervised metabolic medicine.
→ Foundation for Metamed's daily body composition monitoring
DOM
Diabetes, Obesity & Metabolism · 2022
Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension
Wilding JPH, Batterham RL, Davies M, Van Gaal LF et al.
~⅔ of semaglutide weight loss regained within 12 months of stopping, alongside full reversal of cardiometabolic improvements. Physician-led monitoring cannot end when the prescription begins.
→ Defines the clinical continuity gap MetAi addresses
JAMA
JAMA · 2024
Continued treatment with tirzepatide for maintenance of weight reduction: the SURMOUNT-4 randomized clinical trial
Aronne LJ, Sattar N, Horn DB, Bays HE, Riesmeyer JS et al.
89.5% of weight loss maintained with continued tirzepatide versus near-complete reversal on placebo. Outcomes are a function of continuity — the scientific foundation for MetAi's ongoing care model.
→ Model for MetAi's retention architecture
BMC
BMC Public Health · 2024
Leveraging continuous glucose monitoring as a catalyst for behaviour change: a scoping review
Jospe MR, Richardson KM, Saleh AA, Bohlen LC, Crawshaw J, Liao Y et al.
Continuous biological feedback — not periodic measurement — is the primary mechanism of sustained dietary and activity behaviour change across 31 RCTs. Validates MetAi's always-on monitoring over snapshot-based approaches.
→ Validates daily monitoring frequency
JCSM
Journal of Cachexia, Sarcopenia & Muscle · 2025
Association of cumulative visceral fat exposure with cardiovascular disease and all-cause mortality: a prospective cohort study
Liu Q, Cui H, Si F, Wu Y, Yu J · Kailuan Study cohort
Cumulative exposure to high visceral fat — sustained over years — is independently associated with increased CVD and all-cause mortality risk. Visceral fat is a longitudinal longevity metric, not a snapshot.
→ Establishes visceral fat trend monitoring as a longevity standard
eClinMed
eClinicalMedicine (The Lancet) · 2026
Trajectory of weight regain after cessation of GLP-1 receptor agonists: systematic review and nonlinear meta-regression
Systematic review · PROSPERO-registered · Search through August 2025
Weight regain post-GLP-1 cessation is rapid, consistent, and population-wide — independent of drug, dose, and treatment duration. Confirms the need for structured monitoring protocols through and beyond GLP-1 treatment.
→ Informs GLP-1 discontinuation & off-ramp monitoring
Healthspan
Healthspan Research Review · 2025
The Muscle–Longevity Connection: the science of preserving muscle with age
Synthesised review · gethealthspan.com · September 2025
Muscle mass and grip strength predict longevity more reliably than BMI. Sarcopenia correlates with faster progression on biological ageing clocks. Lean mass preservation in metabolic treatment is a longevity intervention — not cosmetic.
→ Frames lean mass monitoring as longevity intervention
Fam Pract
Family Practice · Oxford Academic · 2020
Patient-centredness and behaviour change for weight loss in physician-led care
Oxford Academic
Only 20% of overweight individuals successfully sustain ≥10% weight loss — and those who do overwhelmingly succeed within a continuous, individualised physician-led partnership. The evidence base for Metamed's clinical model.
→ Foundation for Metamed's physician-first care model

A note on our own data

Metamed is a physician-led clinical operator. We do not yet have a published internal outcomes dataset — every statistic on this page is sourced directly from peer-reviewed literature, cited with full authorship, journal, and year. We will share our own outcomes data transparently as it matures.

The research above reflects the evidence base that informed how we designed MetAi — not marketing claims. To review any of the full papers referenced here, email contactus@metamed.health.

Begin Your Journey

Longevity is a decision.
Make it intentional.